Figure 3 | Translational Psychiatry

Figure 3

From: Adenosine A2A receptor and ERK-driven impulsivity potentiates hippocampal neuroblast proliferation

Figure 3

Unpredictability of reward delivery and A2AR antagonism exacerbates impulsivity during the 5-CSRTT. (a) Schematic of experimental design for testing impulsivity during the 5-CSRTT under a random internal trial-interval (rINT-TI). (b) Mice administered (i.p.) ZM-241385 and subjected to rINT-TI aperture illuminations, display significantly higher impulsive premature nosepokes. *P<0.05 by Student’s t-test. (c) Mice administered ZM-241385 and subjected to a rINT-TI show significantly higher impulsive TOI nosepokes. *P<0.05 by Student’s t-test. (d) Both treatment groups performed the 5-CSRTT equally well, as our analysis did not detect a difference in the percentage of correct trials completed. (e) An examination of the percentage of incorrect trials revealed that mice administered ZM-241385 had significantly higher errors during 5-CSRTT performance. *P<0.05 by Student’s t-test. (f) Mice treated with ZM-241385 had a significantly lower percentage of omissions during the 5-CSRTT. (g) Schematic of experimental design for testing impulsivity during the 5-CSRTT under a fixed internal trial-interval (fINT-TI). (h) Mice administered ZM-241385 did not show differences in premature nosepokes during fINT-TI 5-CSRTT performance. (i) Mice administered ZM-241385 or vehicle did not display differences in TOI nosepokes during fINT-TI 5-CSRTT performance. (j) There were no differences between the treatment groups in the percentage of correct trials completed during fINT-TI 5-CSRTT testing. (k) There were no differences between the treatment groups in the percentage of incorrect trials completed during fINT-TI 5-CSRTT testing. (l) There were no differences between the treatment groups in the percentage of omission trials during fINT-TI 5-CSRTT testing. All data are expressed as mean±s.e.m. (b–f n=5–6 per treatment; h–l n=5–6 per treatment) RM two-way ANOVA, #P<0.05 main effect of treatment; *P<0.05 by Tukey’s post hoc multiple comparisons versus vehicle-treated mice. 5-CSRTT, 5-choice serial reaction time task; DRL, differential reward of low rate; RM, repeated measures; TOI, time-out interval.

Back to article page